Rockwell Automation vs Recursion Pharmaceuticals Inc — how do they compare? Rockwell Automation trades at $448.47 (market cap $49.64B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Rockwell Automation is far larger — about 27.4× Recursion Pharmaceuticals Inc's market cap, and Rockwell Automation pays a 1.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ROK | RXRX | |
|---|---|---|
Market Cap | $49.64B | $1.81B |
Sector | Industrials | Health |
52-Week High | $495.08 | $6.79 |
52-Week Low | $333.75 | $2.84 |
Enterprise Value | $52.77B | $1.33B |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $435.22, down 1.32% with a bearish technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and raised 2026 guidance. Valuation metrics appear elevated with P/E of 41.85 and P/S of 5.6, while profitability remains solid with 13.38% net margin. Recent AI integration initiatives and institutional buying activity provide positive catalysts.
ROK presents a mixed outlook with strong operational performance offset by premium valuation. The 16.5% upside to consensus price target of $507 offers potential, but inflation pressures and competitive threats require monitoring. Current technical weakness near support at $432 creates a critical juncture for near-term direction.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Trailing returns across standard periods
Latest headlines on both assets
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →